Balance Sheet for Ligand Pharmaceuticals Incorporated (LGND)

$ 104.69   5.42 (+5.46%) Volume: 849k 4:00 PM EDT Sep 19, 2019
After Hours:  $ 104.69 0.00 (0.00%) Volume: 32.42k 5:07 PM EDT Sep 19, 2019
Statement: View:
Assets [+] in Millions of Dollars
12/2018 12/2017 12/2016 12/2015 12/2014
Cash and Equivalents 117 21 19 97 160
Restrictable Cash 3 - - 1 -
Marketable Securities 647 181 122 103 7
Accounts Receivable 56 26 15 6 13
Loans Receivable - - - - -
Other Receivables - 0 0 1 1
Receivables 56 29 18 12 14
Inventories, Raw Materials - - - - -
Inventories, Work in Progress - - - - -
Inventories, Purchased Components - - - - -
Inventories, Finished Goods - - - - -
Inventories, Other 7 4 2 2 0
Inventories, Adjustments & Allowances - - - - -
Inventories 7 4 2 2 0
Prepaid Expenses - 1 2 1 1
Current Deferred Income Taxes - - - 8 -
Other Current Assets 9 2 2 3 2
Total Current Assets 871 237 163 215 185
Land and Improvements - - - - -
Buildings and Improvement 2 2 2 0 0
Machinery, Furniture and Equipment 5 4 2 3 3
Construction in Progress - - - - -
Fixed Assets, Other - - - - -
Fixed Assets, Total 8 6 3 3 3
Gross Fixed Assets 8 6 3 3 3
Accumulated Depreciation (2) (2) (2) (3) (3)
Net Fixed Assets 5 4 2 0 0
Intangibles 251 248 231 57 55
Cost in Excess 87 86 72 12 12
Non-Current Deferred Income Taxes 47 84 124 189 -
Other Non-Current Assets 0 5 2 0 1
Total Non-Current Assets 390 434 439 288 73
Total Assets 1,261 671 602 503 258
Liabilities [+] in Millions of Dollars
12/2018 12/2017 12/2016 12/2015 12/2014
Accounts Payable 4 2 3 4 8
Short Term Debt 26 225 213 202 0
Notes Payable - - - - -
Accrued Expenses 15 3 4 4 3
Accrued Liabilities 15 3 4 4 3
Deferred Revenues 3 - - 0 0
Current Deferred Income Taxes 30 45 11 (220) 0
Other Current Liabilities 33 9 8 13 11
Total Current Liabilities 82 239 227 223 23
Long Term Debt 610 19 30 40 196
Deferred Income Tax 3 4 0 6 3
Other Non-Current Liabilities 8 14 4 (3) 12
Minority Interest - - - - (2)
Capital Lease Obligations - - - - -
Preferred Securities of Subsidiary Trust - - - - -
Preferred Equity Outside Shareholders' Equity - - - - -
Total Non-Current Liabilities 618 32 33 43 209
Total Liabilities 700 271 260 266 232
Preferred Shareholder's Equity - - - - -
Common Shareholder's Equity 561 400 341 237 26
Common Par 0 0 0 0 0
Additional Paid in Capital 791 798 770 662 681
Cumulative Translation Adjustments - - - - -
Retained Earnings (229) (401) (431) (429) (659)
Treasury Stock - - - - -
Other Equity Adjustments (1) 2 3 5 5
Total Capitalization 1,171 419 371 277 222
Total Equity 561 400 341 237 26
Total Liabilities & Shareholder's Equity 1,261 671 602 503 258
Cash Flow 135 1 (13) 255 11
Working Capital 788 (2) (64) (8) 162
Free Cash Flow 182 86 35 31 16
Invested Capital 1,171 419 371 277 222
Shares Outstanding - Common Class Only 21 21 21 20 20
Preferred Shares Outstanding - - - - -
Total Ordinary Shares 21 21 21 20 20
Total Common Shares Outstanding 21 21 21 20 20
Treasury Shares - - - - -
Basic Weighted Shares Outstanding 21 21 21 20 20
Diluted Weighted Shares Outstanding 24 23 21 21 21